197
Participants
Start Date
May 31, 2015
Primary Completion Date
December 31, 2018
Study Completion Date
January 31, 2019
Seviteronel: given orally once daily in 28-day cycles
Oral Seviteronel given once daily, in continuous 28-day cycles at the recommended Phase 2 dose
Memorial Sloan Kettering Cancer Center, New York
University of Virginia, Charlottesville
Virginia Oncology Associates, Hampton
University of North Carolina, Chapel Hill
Carolina Urologic Research Center, Myrtle Beach
Mayo Clinic - Jacksonville, Jacksonville
Moffitt Cancer Center, Tampa
University of Alabama, Birmingham
Karmanos Cancer Institute, Detroit
University of Wisconsin Carbone Cancer Center, Madison
University of Minnesota, Minneapolis
Washington University, St Louis
GU Research Network, Omaha
Tulane University, New Orleans
Mayo Clinic, Scottsdale
New Mexico Cancer Care Alliance, Albuquerque
University of California at Los Angeles, Los Angeles
University of Washington, Seattle
Yale University, New Haven
Beth Israel Deaconess Medical Center, Boston
Dana-Farber Cancer Institute, Boston
Lead Sponsor
Prostate Cancer Foundation
OTHER
Prostate Cancer Clinical Trials Consortium
OTHER
Innocrin Pharmaceutical
INDUSTRY